Skip to main content

Advertisement

ADVERTISEMENT

Renal Denervation Topic Center

Featured

Cutting-Edge Procedures
05/01/2024

Eric A. Secemsky, MD, MSc, RPVI, FACC, FAHA, FSCAI, FSVM

Director, Vascular Intervention, Beth Israel Deaconess Medical Center; Section Head, Interventional Cardiology and Vascular Research, Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Beth Israel Deaconess Medical Center; Associate Professor of Medicine, Harvard Medical School, Boston, Massachusetts

 

Disclosures: Dr. Secemsky reports he is a consultant to Medtronic and his institution receives funding from Medtronic.

 

Eric A. Secemsky, MD, MSc, RPVI, FACC...
We have struggled for years with managing hypertension. In my own practice, I recognized that I only had so many tools to offer my patients, primarily medical therapy and suggestions on lifestyle changes. However, there were still patients...
We have struggled for years with managing hypertension. In my own practice, I recognized that I only had so many tools to offer my patients, primarily medical therapy and suggestions on lifestyle changes. However, there were still patients...
We have struggled for years with...
05/01/2024
Cath Lab Digest
News
12/04/2023

Medtronic News

Medtronic News
The procedure is approved for use as an adjunctive treatment in patients with hypertension when lifestyle changes and medications do not adequately control blood pressure.
The procedure is approved for use as an adjunctive treatment in patients with hypertension when lifestyle changes and medications do not adequately control blood pressure.
The procedure is approved for...
12/04/2023
Cath Lab Digest
Michael J. Bloch headshot
Videos
11/22/2023

Michael J. Bloch, MD

Michael J. Bloch, MD
Michael J. Bloch, MD, discusses hypertension and a patient-level pooled analysis of ultrasound renal denervation in the sham-controlled RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO trials.
Michael J. Bloch, MD, discusses hypertension and a patient-level pooled analysis of ultrasound renal denervation in the sham-controlled RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO trials.
Michael J. Bloch, MD, discusses...
11/22/2023
Journal of Invasive Cardiology
From Journal of Invasive Cardiology
FDA Approval
11/20/2023

Medtronic News

Medtronic News
Manufacturing of the device for U.S. distribution is already underway, and Medtronic hopes to make it widely available soon to physicians and healthcare systems.
Manufacturing of the device for U.S. distribution is already underway, and Medtronic hopes to make it widely available soon to physicians and healthcare systems.
Manufacturing of the device for...
11/20/2023
Cath Lab Digest
FDA Approval
11/08/2023

Recor Medical News

Recor Medical News
The RADIANCE global program studied the Paradise system in three independently powered, sham-controlled, randomized clinical trials in over 500 patients with uncontrolled hypertension.
The RADIANCE global program studied the Paradise system in three independently powered, sham-controlled, randomized clinical trials in over 500 patients with uncontrolled hypertension.
The RADIANCE global program...
11/08/2023
Cath Lab Digest
SCAI Statement
08/21/2023

Society for Cardiovascular Angiography & Interventions (SCAI) News

Society for Cardiovascular Angiograph...
Despite advocacy for lifestyle interventions and the availability of medications to address hypertension (HTN), more than one half of individuals with high blood pressure do not achieve recommended treatment goals.
Despite advocacy for lifestyle interventions and the availability of medications to address hypertension (HTN), more than one half of individuals with high blood pressure do not achieve recommended treatment goals.
Despite advocacy for lifestyle...
08/21/2023
Cath Lab Digest
Research @ACC
05/17/2021

American College of Cardiology News

American College of Cardiology News ...
Median blood-pressure reduction of 4.5 mmHg seen in treatment group compared with sham WASHINGTON (May 16, 2021) - Two months after undergoing renal denervation (RDN), patients with high blood pressure who did not respond to treatment with...
Median blood-pressure reduction of 4.5 mmHg seen in treatment group compared with sham WASHINGTON (May 16, 2021) - Two months after undergoing renal denervation (RDN), patients with high blood pressure who did not respond to treatment with...
Median blood-pressure reduction...
05/17/2021
Cath Lab Digest

Advertisement

Advertisement

Advertisement